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1. Introduction
1.1. Angiotensin-Converting Enzyme Inhibitors
1.1.1. History
In the 1950s, it was discovered that angiotensin exists as both an inactive decapeptide angio‐
tensin I and an active octapeptide angiotensin II. Human angiotensin-converting enzyme
contains 277 amino-acid residues and has two homologous domains, each with a catalytic site
and a region for binding Zn+2 [1, 2]. The degradation of bradykinin to inactive peptides occurs
via action of ACE; ACE thus not only produces a potent vasoconstriction but also inactivates
a potent vasodilator. In 1965, Ferreira [3] studied the physiological effects of snake poisoning
and discovered a specific component from the venom of the pit viper, Bothrops jararaca, which
inhibits degradation of the peptide bradykinin and potentiate hypotensive action of bradyki‐
nin potentiating factors (BPFs), basically amino-acid-containing peptides. Bakhle [4] reported
that these same peptides had an inhibitory activity on ACE of dog lung homogenate and
inhibited the enzymatic conversion of angiotensin I to angiotensin II. Brunner and Laragh [5]
administered them to hypertensive patients and found them to be extremely effective in
lowering blood pressure. The structural requirements for substrates of angiotensin-converting
enzyme to cleave a substrate are found to be similar to those observed with carboxypeptidase
A of bovine pancreas [6, 7].
The molecule ACE is a zinc metallopeptidase and has a similar mode of action to carboxy‐
peptidase [8]. In 1970, the Bradykinin-potentiating pentapeptide BPP5a was isolated, which
inhibited enzyme angiotensin and decreased blood pressure [9]. The significance of ACE in
the pathogenesis of hypertension was not fully appreciated until 1977, when Ondetti [10] first
isolated and then synthesized the naturally occurring non-peptide, teprotide. He proposed a
hypothetical model of the active site of ACE and used it to predict and design compounds that
would occupy the carboxy-terminal binding site of the enzyme captopril, a specific potent
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inhibitor of ACE. Clinical trials showed excellent anti-hypertensive properties and these
results had a major impact on the treatment of cardiovascular disease [11]. The first demon‐
stration of an orally active ACE inhibitor was made on 31 March 1975, when the succinyl group
was replaced with a derivative of cysteine, increasing inhibitory potency about 2,000-fold
because sulphhydryl of cysteine bound with zinc more tightly than the carboxyl of succinyl.
This resulted in captopril, with a dramatic effect on renal function and on hypertension [12].
Enalapril is basically a first derivative of ACE inhibitor, which was developed to overcome the
limitations of captopril. Lisinopril is a lysine analogue of enalaprilat (the active metabolite of
enalapril). In vitro lisinopril is slightly more potent than enalaprilat. It is a non-sulphhydryl
angiotensin-converting-enzyme (ACE) inhibitor active without metabolism and is absorbed
in its active form.
1.1.2. Chemistry
Angiotensin enzyme inhibitors are basically ester-containing drugs that show 100-1000 times
less activity than their active form; these inhibitors are synthetic in nature and can be classified
on the basis of their chemical structure. They can be grouped as sulphhydral-containing
(fentiapril, pivalopril, zofenopril, alacepril, etc.), dicarboxyl-containing (lisinopril, benazepril,
quinapirl, perindopril, indopril, pentopril, indalapril, alazapril, moexipril, romipril, spirapril,
etc.), phosphorous-containing (fosinopril) [13] and naturally occurring lactokinins and
casokinins. [14]
Drug Nomenclature Structure Ref
Enalapril (S)-1-[N-[1-(ethoxycarbonyl)-3-phenyl propyl]-L-alanyl]-L-proline,(Z)-2-butenedioate salt [15]
Captopril 1-(3-mercapto-2-dmethyl-1-oxopropyl)-1-proline (S,S) [16]
Lisinopril ((S)-1-[N2-(1-carboxy-3-phenylpropyl)-1-lysyl]-1-prolinedehydrate [16]
Table 1. ACE Inhibitors with structure and nomenclature
In general we can say that all ACE inhibitors differ by three properties: potency, conversion
from pro-drug to active form, and pharmacokinetics (i.e., ADME). They also differ in terms of
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tissue distribution. All ACE inhibitors have a similar antihypertensive efficacy – they effec‐
tively block the conversion of angiotensin 1 to angiotensin II – and all have similar therapeutic
indications, adverse effect profiles and contraindications.
1.1.3. Mechanism of action
These inhibitors block the converting enzyme of angiotensin, which is responsible for cleavage
from angiotensin I, which is decapeptide, to angiotensin II, which is octapeptide [17, 18], and
lower the BP by reducing PVR (peripheral vascular resistance). They also decrease aldosterone
secretion and the resulting sodium and water retention.
1.1.4. Pharmacokinetics
The oral bioavailability of ACE inhibitors ranges from 13% to 95% [19, 20]. Most ACE inhibitors
are administered as pro-drugs that remain inactive until esterified in the liver [21]. Pharma‐
kokinetic characteristics of different ACE inhibitors are given in Table 2
Drug Oral resorption
%
Protein binding
%
Elimination half-
life hr
Metabolism Usual dose (mgd-1)
Enalapril 60 <08 11 Partly convertedenalaprilate 5-20
Captopril >25 30 1.7 Partly metabolized 25-50
Lisinopril 25 0 41 Non metabolized 5-20
Table 2. Pharmacokinetic of ACE Inhibitors
1.1.5. Therapeutic use
ACE inhibitors are effective in patients with mild to moderately severe hypertension, normal
or low plasma renin activity, collagen vascular disease and cardiovascular disease [22, 23].
They are also used in the prevention and treatment of myocardial infarction [24, 25] and in the
management of cardiac arrhythmias [26]. They can decrease the progression of atherosclerosis,
microalbuminuria and diabetic retinopathy, and produce a beneficial effect in patients with
Bartter’s syndrome [27].
1.1.6. Adverse effects
ACE inhibitors have a relatively low incidence of side effects and are well tolerated; however,
dry cough is common, appearing in 10-30% of patients. This appears to be related to the
elevation in bradykinin [28-30]. Hypotension is seen especially in patients with heart failure
[31], angiooedema (life-threatening airway swelling and obstruction; 0.1-0.2% of patients) and
hyperkalaemia. ACE inhibitors are contraindicated in pregnancy, in the first trimester
associated with a risk of major congenital malformations, particularly affecting the cardiovas‐
cular and central nervous systems [32]. The most common (≥1% of patients) adverse effects
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include hypotension, fatigue, dizziness, headache, nausea and other gastrointestinal distur‐
bances, dry cough, hyperkalaemia and renal impairment. Rash and taste disturbances are more
prevalent with captopril and are attributed to its sulphhydryl moiety; eosinophilia has also
been reported. Most of the adverse effects are reversible on withdrawing therapy [33].
Treatment with ACE inhibitor has been associated with the development of anaphylactoid
reaction [34].
1.1.7. Drug interactions
Hypotensive effect of ACE inhibitors decreased when given in combination with non-steroidal
anti-inflammatory drugs [35], but this effect was enhanced with calcium-channel blockers and
beta-blockers [36]. Granulocytopaenia occurs after combined therapy of ACE inhibitors and
interferones [37]. ACE inhibitors interact with different drugs, like NSAIDs [38]. Cytokines
antagonize the hypotensive effect of ACE inhibitors [39]; severe hypokalaemia occurs with
potassium-depleting diuretics [40] and potassium-sparing diuretics produce hyperkalaemia
[41, 42]. ACE inhibitors were shown to increase potassium levels in the body [43]. Alpha-
blockers enhance the hypotensive effect of ACE inhibitors [44]. Iron supplementation success‐
fully decreases cough induced by ACE inhibitors [45] and can interfere with the absorption of
ACE inhibitors [46]. Hypoglycaemic effect is enhanced with anti-diabetics and insulin [47,
48]. Combination of azathioprine and ACE inhibitors is associated with anaemia [49]. The risk
of bone marrow depression is increased in patients taking concomitant therapy of ACE
inhibitors and immunosuppressive agents.
1.2. HMG-CoA reductase inhibitors (statins)
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are the
most effective among all hypolipidaemic agents [50]. These lipid-lowering drugs are increas‐
ingly used for primary and secondary hindrance of cardiovascular disease [51]; they have only
been recognized for treatment of hyperlipidaemia. In clinical studies, statins are highly
effective in enhancing HDL levels while reducing total cholesterol, LDL cholesterol, apolipo‐
protein B and triglyceride levels.
The normal treatment regimen for these drugs involves daily exposure over a period of many
years [52, 53]. They have also been examined in combination with cures of multiple sclerosis,
osteoporosis, Alzheimer’s disease and dropping the superfluous increased occurrence in CHD
in women on HRT treatment [54]. They have anti-thrombogenic, anti-inflammatory and
anticoagulant properties [55, 56]. These therapeutic properties are independent of lipid
lowering [57], and the benefits of statins appear to be independent of baseline cholesterol [58].
They can be classified into subclasses: the naturally or fungi-derived first generation, and the
synthetic second generation. The first generation includes simvastatin, lovastatin and pravas‐
tatin, and the second atorvastatin and rosuvastatin. They can be further divided into the
lipophilic group (simvastatin, lovastatin and atorvastatin) and the OH hydrophilic group
(pravastatin and rosuvastatin) [59].
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Statin Nomenclature Structure
Rosuvastatin
(3R,5S,6E)-7-
[4-(4-fluorophenyl)-2-
(N methyl-methanesulphonamido)-6-(propan-2-yl)
pyrimidin -5-yl]-3,5-dihydroxyhept-
6-enoic acid
Atorvastatin
[R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-
(1-methylethyl)-3-phenyl-4[(phenylamino)
carbonyl]-1 H -
pyrrole-1-heptanoic acid
Simvastatin
[1S-[1α,3α,7β,8β(2S*,4S*),
8aβ]]-2,2-dimethyl-butanoic acid1,2,3,7,8,
8a-hexahydro-3,7-dimethyl -8-
[2-(tetrahydro-4-hydroxy-6-oxo-
2H-pyran-2-yl ethyl]-1-
naphthalenyl ester
Pravastatin
[1 S- [1alpha(beta S*, delta S*), 2,
6alpha ,8beta(R*):8]]-1,2,6,7,8,8a-hexahydro-beta,
delta,[6-trihydroxy-2-methyl-8-
[2-methyl-1-oxobutoxy]-1-
phthaleneheptanoic acid salt
Table 3. Statins with structure and chemical name
2. Experiment
2.1. Materials
Raw materials used were of pharmaceutical purity and were obtained from different phar‐
maceutical companies (Table 4). Tablets were purchased from a local pharmacy; each product
was labelled with an expiry date not earlier than two years from the time of these studies.
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Class Drugs Brands Potency
(mg)
Pharmaceutical industry
ACE inhibitors
Enalapril Renitec 10 MSD
Captopril Capoten 25 Bristol Meyers (Pvt.) Ltd.
Lisinopril Lisinopril 5 Atco Laboratories Ltd.
Statins
Rosuvastatin X-plended 20 Pharm Evo (Pvt.) Ltd.
Atorvastatin Atopitar 10 Atco Pharma (Pvt.) Ltd.
Pravastatin Pravachol 20 Bristol Meyers (Pvt.) Ltd.
Simvastatin Atcol 10 Geofman Pharma (Pvt.) Ltd.
Table 4. Drugs, brands and manufacturers
2.1.1. Reagents
Analytical-grade solutions were used for the performance of the experiment. Methanol and
acetonitrile were of HPLC grade and other reagents included HCl, sodium hydroxide (NaOH),
sodium chloride (NaCl), disodium hydrogen orthophosphate, potassium dihydrogen ortho‐
phosphate, ammonium chloride, NH3 solution (10%), phosphoric acid (8%) (Merck Germany).
Organic solvents used were methanol, ethanol, ethyl acetate, chloroform, acetronitrile,
triethylamine and DMSO (Merck HPLC Grade Germany).
2.1.2. Equipment
A UV-visible spectrophotometer (Shimadzu Model 1601, Japan) with 10-mm path length was
connected to a computer with UVPC version 3.9 software. A Stedec CSW-300 was used for
deionization of water. Dissolution was accomplished using BP 2009 standards. Chromato‐
graphic studies were carried out by using two Shimadzu HPLC systems, one equipped with
an LC-10 AT VP pump (SPD-10 A VP), and the second with an LC-20AT UV/VIS detector
utilizing Hypersil, ODS, C18 (150×4.6 mm, 5 micron) and a Purospher® STAR RP-18 column.
Chromatographic data peaks were analysed using Shimadzu Japan CBM-102, class GC 10
software.
Infrared studies were performed using Shimadzu FTIR Prestige-21. Spectral analysis was
performed using Shimadzu software. The proton H1-NMR spectra were calculated on a Bruker
(AMX 500 MHz) spectrometer using TMS as an internal standard. Melting points were
recorded using Gallen kamp melting-point apparatus Minnesota Mining And Manufacturing
Company.
2.2. Methods
2.2.1. Preparation of simulated gastric juice and buffers
0.1 N HCl was prepared by using 9 mL HCl (11 N) in a volumetric flask; the volume was made
up with de-ionized water. Chloride buffer at pH 4 was prepared by dissolving 3.725 g of KCl
(potassium chloride) in deionized water and 0.1N HCl was used for pH adjustment. For
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preparation of PO4 (phosphate buffer pH 7.4) 0.6 gm of potassium dihydrogen orthophosphate
was used, plus 6.4 g of disodium hydrogen orthophosphate and 5.85 g of NaCl (sodium
chloride), and the pH was adjusted. Preparation of NH3 ammonia buffer at pH 9 was done
using 4.98 g of NH4Cl ammonium chloride and pH-adjusted with 10% ammonia.
2.2.2. Construction of the calibration curve of drugs
The above standard solutions of all drugs were scanned in the region 200-700 nm against the
reagent blank, and absorbance maxima were recorded as shown in Table 5. Calibration curves
were constructed between concentration and absorbance. Epsilon values and linear coeffi‐
cients were calculated in each case at all the above-described pH values. Beer Lambert’s law
was obeyed at all concentrations and pHs.
Class of drugs Analytes Wavelength (nm) Conc. range
(m Mole)
ACE inhibitors
Enalapril 203, 206, 207, 208 1-9 x 10-5
Captopril 203, 204, 206 5 -14 x 10-7
Lisinopril 206 1-10 x 10-5
Statins
Atorvastatin 241 0.5-4.5 × 10-2
Rosuvastatin 240 1-5 × 10-5
Simvastatin 231, 238, 246 1-9 × 10-5
Pravastatin 235 1-9 × 10-5
Table 5. Please Add Caption
2.2.3. Monitoring of drug interactions of enalapril, captopril and lisinopril by high-performance liquid
chromatography
HPLC methods for simultaneous determination of enalapril, captopril and lisinopril with
statins in raw materials, pharmaceutical dosage forms or in human serum were developed and
validated according to ICH guidelines. These methods were then applied to drug-drug, drug-
metals and drug-antacid interaction studies.
2.2.4. Chromatographic conditions
Isocratic elution was performed at ambient temperature with two different types of column.
Hypersil, ODS, C18 (150×4.6 mm, 5 micron) and Purospher® STAR RP-18, for assay of
enalapril, captopril and lisinopril and simultaneous determination of these drugs with
interacting drugs, respectively. The mobile phase, flow rate, wavelength and UV detection
were varied as shown in Table 6. A sample volume of 20 μL was injected in triplicate onto the
HPLC column and the elute was monitored at different wavelengths.
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2.2.5. Preparation of standard solutions
Stock reference standard solutions of all drugs were prepared daily by dissolving appropriate
amounts of each drug in mobile phase to yield final concentration of 300 μgmL-1. For the
calibration standards, calibrators of each drug were prepared by making serial dilutions from
stock solutions. All solutions were filtered through 0.45 μm filter and degassed using sonicator.
2.2.6. Preparation of pharmaceutical dosage from samples
Pharmaceutical formulations of the respective brands commercially available in Pakistan were
evaluated. In each case, groups of 20 tablets were individually weighed and finely ground in
a mortar. The portion of the powder equivalent to the amount of drug was transferred into a
volumetric flask and completely dissolved in mobile phase, and then diluted with this solvent
up to the mark. After filtration using a 0.45 micrometre μm filter this was then injected.
2.2.7. Preparation of standard plasma solutions
Samples of blood used were collected then centrifuged at 3000 rpm for at least ten minutes,
Supernatant solution was stored at –20°C. The solution serum was deprotinated by using
(ACN) acetonitrile, and this solution was spiked daily with working solutions for required
concentrations of ACE inhibitors and interacting drugs (statins). 10 μL of sample was injected
and chromatographed under the above conditions.
Drug Mobile phase pH Flow rate Detection
MeOH ACN H2O mLmin-1 nm
Enalapril assay 70 - 30 3.5 1 215
Enalapril + statins 60 40 3 1.8 230
Captopril 50 - 50 2.9 1 220
Captopril + statins - 60 40 2.9 1.5 230
Lisinopril 80 2.5 17.5 3 1 225
Lisinopril + statins - 60 40 3 1 225
Table 6. Chromatographic conditions of HPLC methods
2.2.8. Method development and optimization
HPLC methods were developed and optimized for certain parameters before method valida‐
tion. The optimization of the analytical procedure was carried out by varying the mobile-phase
composition, flow rate, pH of the mobile phase, diluent of solutions and wavelength of analytes
in order to achieve symmetrical peaks with good resolution at reasonable retention time.
2.2.9. Method validation
All validation parameters were established according to the guidelines given by ICH: system
suitability, linearity, selectivity of drugs, specificity, (concentration-detector response rela‐
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tionship), accuracy or precision and sensitivity with systems, i.e., D and Q (detection and
quantification) limit.
Specificity and linearity
The drugs were spiked with pharmaceutical formulations containing different excepients. The
linearity of the proposed method was checked at different levels of concentration with different
groups. Correlation coefficient was linear; intercept and slope values were also calculated.
Suitability of system
The system suitability of the method was evaluated by analysing five replicate analyses of the
drug at a specific concentration for repeatability, (peaks) symmetry factor, theoretical plates
for columns, resolution of peaks between interacting drugs, and relative retention of drugs.
Accuracy and precision
Accuracy was calculated at three different levels of concentration (80±20%) by spiking a known
amount of the drug. Three or four injections of each drug were injected into the system and
the percentage recovery was calculated.
For precision, six replicates of each level were injected into the system on two different non-
consecutive days in each case, and the %RSD was calculated.
Limit of detection and quantification
The detection limit (LOD) of the method was calculated by the formula LOD = 3.3 SD/slope.
The quantitation limit (LOQ) – the lowest level of analyte that is accurately measured – was
set at ten times the noise level (LOQ = 10ơ/S, where ơ is the standard deviation of the lowest
standard concentration and S is the slope of the standard curve).
Robustness
Robustness was established by changing the concentration of mobile phase (water, methanol
and acetonitrile), wave length, flow rate and pH. At least five repeated solutions were used
with small variations of different parameters. Parameters that were changed mainly had a
small deviation: ± 0.2% flow rate/pH, and ±5% for wave length.
Ruggedness
Ruggedness was determined in different labs. Lab 1 was the (RIPS) Research Institute of
Pharmaceutical Sciences, Faculty of Pharmacy, Karachi University, and the other at the same
university in the Department of Chemistry. Two different instruments (LC 10/LC 20) and two
different columns (Purospher STAR C18/Hypersil ODS) were used.
2.2.10. Interaction studies by HPLC
Enalapril solution was mixed with a solution of the interacting drug (statins), which gave a
final concentration of 100 μgmL-1 for each constituent). These solutions were kept in a water
bath at 37 °C for three hours. An aliquot of 5 mL was withdrawn at 30-minute intervals; after
making appropriate dilutions it was filtered through 0.45 μ filter paper and three replicates
were injected into the HPLC system. The concentration of each drug was determined and the
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percentage recovery was calculated; the same procedure was applied for captopril and
lisinopril.
2.3. Synthesis of ACE inhibitors and interacting-drugs complexes
Complexes of enalapril, captopril and lisinopril with all interacting drugs were synthesized.
Equimolar solutions of enalapril and interacting drugs were prepared in methanol. An
equivolume solution of enalapril was mixed with each drug individually and the respective
pH was adjusted either by 1-2 drops of ammonia or 0.1 N HCl. These mixtures were refluxed
for three hours then filtered and left for crystallization at room temperature. Melting points
and physical characteristics of these complexes were noted. Solubility of all these complexes
was checked in different solvents: water, methanol, ethanol, chloroform and DMSO. A similar
procedure was adopted for captopril and lisinoril.
2.3.1. Spectroscopic studies of complexes
2.3.1.1. Infrared studies
ACE inhibitors and their complexes were characterized by using a FT-IR spectrophotometer
in the region 400-4000 cm-1. The infrared spectra were recorded using a potassium bromide
disc. ATR (attenuated total reflection) or smart performer accessory was used for the sample
(minimum amount).
2.3.1.2. Proton NMR analysis
Proton 1H NMR analysis was performed using a Bruker instrument in deuterated H2O,
chloroform and methanol using (TMS) tetramethyl silane as an IS (internal standard).
3. Results and discussion
3.1. Method development/validation by HPLC
Simple, cheap and very precise, HPLC was used for the determination of ACE inhibitors
(captopril, enalapril and lisinopril) in the presence of different statins: ROS (rosuvastatin), ATR
(atorvastatin) and SMV(simvastatin) in active ingredients as well as in formulations. It was
developed according to guidelines ICH. All inhibitors with statins separated out in less than
10 mins without interference from any ingredients. The recovery of drugs was within the
desired range (99-102%). These methods were validated according to ICH and the criteria for
acceptance (accuracy/linearity/precision/specificity) and for system suitability were met. The
methods can easily be used for quantitative analysis of ACE inhibitors and statins as single
drugs or in formulations.
3.2. Interaction of ACE inhibitors with statins
Hyperlipidaemia and hypertension correlate with each other. They can effect coronary heart
disease (CHD), because cardiovascular disease (CVD) is closely related to different factors,
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such as hypertension (HT) or high cholesterol levels. Factors include family history, age, sex,
and diabetes [60-66]. Co-administration of antihypertensive, lipid-lowering and antidiabetic
drugs is used in the treatment [67-72]. The most commonly used combinations of diuretic
(chlorthalidone, hydrochloroth-iazide, etc.) and an angiotensin II receptor antagonist to
control hypertension, as well as with a statin (fluvastatin, simvastatin, etc.) to reduce the
cholesterol [73]. Co-administration of an antihypertensive agent with statin is an effective
therapeutic option for treatment of multiple cardiovascular risk factors, and especially for high
blood pressure (BP) and LDL-C [74-78]. In addition, statins may improve the vasodilatation
capacity of large arteries and may thus contribute to BP-lowering in patients treated with both
an anti-hypertensive and a statin [79]. Hypercholesterolaemia is often accompanied by
hypertension, an associated risk factor for coronary-artery disease (CAD) [80-82]. ACE
inhibitors are effective for the management of hypertension, supraventricular arrhythmias and
angina pectoris. Other antihypertensive drugs such as propranolol [83] and atenolol [84] also
interact with HMG-CoA reductase inhibitor. In the light of the above results, ACE inhibitors
may interact and effect a change in each other’s availabilities. Methods were developed by
HPLC for both ACE inhibitors and statins before starting interaction studies [85-88]. In vitro”
interactions of ACE inhibitors with statins (atorvastatin, rosuvastatin, pravastatin and
simvastatin) were studied in stimulated body environments utilizing the HPLC technique.
3.2.1. Interaction of enalapril with statins using HPLC
In vitro interactions of enalapril in the presence of statins drugs (rosuvastatin, atorvastatin and
simvastatin) were observed in 1:1 ratio buffers of pH 4 and 7.4 at 37°C. Simultaneous deter‐
mination of both interacting drugs was also developed, as described above. The results are
summarized in Table 7 and Figures 1-3. There was no significant increase or decrease in the
concentration of enalapril and interacting drugs at pH 4 and pH 7.4. When enalapril interacted
with rosuvastatin, atorvastatin and simvastatin, concentration remained at nearly 99-103% at
pH 4 and 99-107% at pH 7.4. Collectively, in vitro interaction of enalapril with rosuvastatin,
atorvastatin and simvastatin using HPLC at pH 4 and pH 7.4 did not show any significant
interactions.
Time % Availability at pH 4 % Availability at pH 7.4
min ENP ROS ENP ATR ENP SIM ENP ROS ENP ATR ENP SIM
0 100 100 98 98.3 99 99.8 100 99 99 99.99 99.02 99.97
30 100 100 99 99.3 100 101 99.78 99 98 100 99.9 99.9
60 99 100 104 98.3 99 101 98.99 95 98 102 99.99 100.3
90 100 101 100 99.4 100 102 102.6 106 106 101.8 100.3 100
120 100 100 104 99.4 101 102 99.79 106 104 101.9 101 101.3
150 100 100 101 99.4 100 103 98.93 106 105 102.6 101.3 102.1
180 100 100 99.7 102 101 102 102 106 107 106.5 102 103
Table 7. Percentage availability of enalapril and statins at pH 4 and 7.4 using HPLC
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Figure 1. Percentage availability of enalapril and statins at pH 4
Figure 2. Percentage availability of enalapril and statins at pH 7.4
3.2.2. Interaction of captopril with statins using HPLC
In vitro interactions of captopril in the presence of statins drugs (rosuvastatin, atorvastatin and
simvastatin) were observed in 1:1 ratio solutions at 37°C. Simultaneous determination of both
interacting drugs was also developed, as described above. Interaction results (Table 8 and
Figure 3) show that availability of all drugs was 100% at zero minutes; after that, availability
of atorvastatin and simvastatin increased in ascending order, but the percentage availability
of captopril decreased in the presence of atorvastatin and simvastatin and remained the same
in the presence of rosuvastatin. The availability of atorvastatin and simvastatin was 173% and
115% after 180 min, respectively. Retardation effect was observed at availability of captopril
of 97.8%, and 58.2% was available at the end of experiment. Rosuvastatin showed no effect on
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captopril and availability of rosuvastatin and captopril at the end of experiment was 100% was
99.12%, respectively.
Time min CAP ROS CAP ATOR CAP SIM
0 100 100.4 100.3 100 100.7 100.3
30 100.2 100.4 100.3 101.5 100.36 100.23
60 100.3 100.3 101.3 100.3 62.1 105.3
90 100.2 99.98 100.2 102.2 67.3 108.2
120 99.9 99.69 100.2 160.8 59.3 110.3
150 100.3 99.87 98.9 162.1 59.3 113.6
180 100.2 99.12 97.8 173.1 58.2 115.6
Table 8. Percentage availability of captopril and statins using HPLC
 
Figure 3. Chromatogram showing change in AUC of drugs. CAP+ATR, CAP+ROS and CAP+SIM (pink before and
black after interaction).
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3.2.3. Interaction of lisinopril with statins using HPLC
In vitro interactions of lisinopril in the presence of statin drugs (pravastatin, rosuvastatin and
atorvastatin) were carried out in solution of 1:1 ratio at 37°C. Simultaneous determination of
these interacting drugs was also developed as described above. Results of these interactions
(Table 9 and Figure 4) show that when lisinopril interacted with pravastatin, rosuvastatin and
atorvastatin its concentration remained in the range 100.3- 102%, 99.9-101.4% and 99.36-102%
at 37°C. Pravastatin, rosuvastatin and atorvastatin amplified the availability of lisinopril,
unaffected at 37 °C using HPLC. Availability of pravastatin and rosuvastatin after interaction
almost stayed unchanged at 37 °C. Interactions of lisinopril in the presence of atorvastatin
showed that availability of atorvastatin was enhanced, while that of lisinopril after interaction
was unchanged. Collectively, in vitro interaction of lisinopril with rosuvastatin, atorvastatin
and simvastatin using HPLC at 37 °C did not show any significant results.
Time min LIS PRA LIS ROS LIS ATOR
0 100.3 99.98 99.98 100.3 99.36 97.34
30 100.6 99.63 99.36 100.2 101.5 100.2
60 100.3 99.36 101 100.6 101.3 105.2
90 100.6 100.3 101 100.2 102.5 106.3
120 100.9 100.3 102.3 100.9 101.1 106.20
150 102.0 100.3 102.3 100.4 102.4 106.2
180 102.3 101.3 101.4 100.5 102.4 106.02
Table 9. Percentage availability of lisinopril and statins using HPLC
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4. Conclusion
Interaction studies suggest that enalapril and lisinopril are not affected by statins but captopril
changes the availability of drugs. In vivo studies are required to prove this relationship.
Author details
Safila Naveed*
Address all correspondence to: safila117@gmail.com
Faculty of pharmacy, Jinnah University for Women Karachi, Pakistan
References
[1] Bernstein KE, Martin BM, Edwards AS and Bernstein EA (1989) Mouse angiotensin-
converting enzyme is a protein composed of two homologous domains, J. Biol.
Chem., 264, 11945-11951.
[2] Soubrier F, Alhene-Gelas F, Hubert C, Allegrini J, John M, Tregear G and Corvol P
(1988) Two putative active centres in human angiotensin I-converting enzyme re‐
vealed by molecular cloning, Proc. Natl. Acad. Sci., 85, 9386-9390.
[3] Ferreira SH (1965) A bradykinin-potentiating factor present in the venom of Bo‐
throps jararaca, Brit. J. Pharmacol., 24, 163-169.
[4] Bakhle YS (1968) Conversion of angiotensin I to angiotensin II by cell free extracts of
dog lung, Nature, 220, 919-21.
[5] Brunner HR, Laragh JH, Sealey JE, Gavras I and Vukovich RA (1974) An angiotensin
converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors
in hypertensive patients, New Eng. J. Med., 291, 817-821.
[6] Hartsuck JA and Lipscomb WN (1971) Carboxypeptidase A, In the Enzymes, Vol 3, ed.
P.D. Boyer., pp l-56, New York, Academic Press.
[7] Hofmann K and Bergmann M (1946) The specificity of carboxypeptidase, J. Biol.
Chem., 134, 225-235.
[8] Quiocho F and Lipscomb WN (1971) Carboxypeptidase A, A protein and an enzyme,
Adv. Protein. Chem., 25, l-78.
[9] Ferreira SH, Bartelt DC and Greene LJ (1970) Isolation of bradykinin potentiating
peptides from Bothrops jararaca venom, Biochemistry, 9, 2583- 2593.
Interaction Studies of ACE Inhibitors with Statins
http://dx.doi.org/10.5772/59491
217
[10] Ondetti MA, Rubin B and Cushman DW (1977) Science, 196, 441-444.
[11] Maxwell RA and Eckhadt SB (1990) Captopril Drug Discovery, 19, 34.
[12] Cushman DW, Ondetti MA, Gordon EM, Natarajan S, Karanewsky DS, Krapcho J
and Petrillo EW (1980) Rational Design and Biochemical utility of specific inhibitors,
Journal of Cardiovascular Pharmacology: 7, S17-30.
[13] G a G(1996) The Pharmacological Basis of Therapeutic, 9th edition McGraw-Hill Press,
New York p. 744.
[14] Fitz Gerald RJ, Murray BA and Walsh DJ (2004) Hypotensive peptides from milk
proteins, J Nutr., 134, 980S-8S.
[15] Aloysius TN, Kelly C, Pierre R and Edward DS (2006) Synthesis and molecular mod‐
eling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting en‐
zyme. Bioorganic and Medicinal Chemistry Letters, 17(1), 4616-4619.
[16] Sweetman SC and M (2005) The Complete Drug Reference, Pharmaceutical Press, Lon‐
don & Chicago, 34th Ed., 900-901.
[17] Richard AH and Pamela CC (1977) Illustrated Review Pharmacology, Lippincott-Raven
Publishers, Philadelphia, Revised ed., 151-162.
[18] Bertam GK (1998) Basic and Clinical Pharmacology, Appleton and Lange, Revised ed.,
197-213 Stamford.
[19] Riley TN and De Ruiter J (1992) New drugs, U.S. Pharmacist., 17(3), 42-46.
[20] Riley TN and DeRuiter (1997) New Drugs, U.S. Pharmacist, 22(3)175-176.
[21] Leonetti G and Cuspidi C (1995) Choosing the right ACE inhibitor: A guide to selec‐
tion, Drugs, 49, 516-535.
[22] Burris JF (1995) the expanding role of angiotensin-converting enzyme inhibitors in
the management of hypertension, J. Clin. Pharmacol., 35, 337-342.
[23] The 1998 report of the Joint National Committee on the Detection, Evaluation and.
Treatment of High Blood Pressure, Arch. Intern. Med., 1998; 148, 1023-1038.
[24] Borghi C and Ambrosioni E (1996) A risk-benefit arrestment of ACE inhibitor thera‐
py post-myocardial infarction, Drug Safety, 14, 277-87.
[25] Murdoch DR and McMurray JJV (1998) ACE inhibitors in acute myocardial infarc‐
tion, Hosp. Med., 59, 111-15.
[26] Deedwania PC (1990) Angiotensin converting enzyme inhibitors in congestive heart
failure, Arch. Intern. Med., 150, 1798-1805.
[27] Jest P (1991) Angiotensin-converting enzyme inhibitors as a therapeutic potential in
Bartter’s syndrome, Eur. J. Clin. Pharmacol., 41, 303-5.
Hypercholesterolemia218
[28] 28 Okumura H, Nishimura E and Kariya S (2001) Angiotensin-converting enzyme
(ACE), 121(3), 253-7.
[29] Anonymous (1994) Cough caused by ACE inhibitors, Drug Ther. Bull., 32(28)55-56.
[30] Ravid D (1994) ACE-inhibitors and cough: a prospective evaluation in hypertension
and congestive heart failure, J. Clin. Pharmacol., 34, 1116-1120.
[31] Parish RC and Miller IJ (1992) Adverse effects of angiotensin-converting enzyme in‐
hibitors: an update, Drug Safety, 7, 14-31.
[32] Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S and Gideon PS
(2006) Major congenital malformations after first-trimester exposure to ACE inhibi‐
tors, N. 33 Engl. J. Med., 354(23), 2443-51.
[33] Molinaro G, Cugno M and Perez M (2002) Angiotensin-converting enzyme inhibitor-
associated angioedema is characterized by a slower degradation of des-arginine(9)-
bradykinin, J. Pharmacol. Exp. Ther., 303, 232-7.
[34] Verresen L (1990) Angiotensin-converting-enzyme inhibitors anaphylactoid reactions
to high-flux membrane dialysis, Lan., 336, 1360-1362.
[35] Koopman PP, Van Megan T, Thien I and Gribrav FWJ (1989) The interaction between
indomethacine and captopril or enalepril in normal volunteers, Journal of Internal
Medicine, 226, 139-142.
[36] Bainbridge AD, MacFadyen RJ, Lees KR and Reid JL (1991) A study of the acute
pharmacodynamic interaction of ramipril and felodipine in normotensive subjects,
Br. J. Clin. Pharmacol., 31, 148-53.
[37] Casato M (1995) Granulocytopenia after combined therapy with interferone and an‐
giotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxic‐
ity, Am. J. Med., 99, 386-91.
[38] Shionoiri H (1993) Pharmacokinetic drug interactions with ACE inhibitors, Clin.
Pharmacokinet., 25(1), 20-58.
[39] Shionoiri H, Naruse M, Minamisawa K, Ueda S, Himeno H, Hiroto S, Takasaki I
(1997) Fosinopril clinical pharmacokinetics and clinical potential, Clin. Pharmacoki‐
net., 32(6), 460-80.
[40] D’Costa DF, Basu SK and Gunasekera NPR (1990) ACE inhibitors and Diuretics caus‐
ing hypokalemia, B.J.C.P., 44, 26-7.
[41] Shionoiri H (1993) Pharmacokinetic drug interactions with ACE inhibitors, Clin.
Pharmacokinet., 25(1), 20-58.
[42] 42 Mignat C and Unger T (1995) ACE-inhibitors: Drug interaction of clinical signifi‐
cance, Drug Safety, 12, 334-7.
Interaction Studies of ACE Inhibitors with Statins
http://dx.doi.org/10.5772/59491
219
[43] Good CB, McDermott L and McCloskey B (1995) Diet and serum potassium in pa‐
tients on ACE inhibitors, JAMA, 274, 538.
[44] Baba T, Tomiyama T and Takebe K (1990) Enhancement by ACE inhibitors of first
dose hypotension caused by an alpha1-blocker, N. Eng. J. Med., 322, 1237.
[45] Lee SC, Park SW and Kim DK (2001) Iron supplementation inhibits cough associated
with ACE inhibitors, Hypertension, 38, 166-170.
[46] Campbell NR and Hasinoff BB (1991) Iron supplements, a common cause of drug in‐
teractions, Br. J. Clin. Pharmacol., 31, 251-255.
[47] Herings RMC (1995) Hypoglycemia associated with use of inhibitors angiogenesin
converting enzyme, Lancet, 345, 1195-8.
[48] Morris AD (1997) ACE inhibitors’ use is associated with hospitalization for severe
hypoglycemia in patients with diabetes, Diabetes Care, 20, 1363-7.
[49] Gossmann J, Kachel HG, Schoeppe W and Scheuermann EH (1993) Anemia in renal
transplant recipients caused by concomitant therapy with azathioprine angiotensin-
converting enzyme inhibitors, Transplantation, 56, 585-9.
[50] Goldstein JL and Brown MS (1990) Regulation of the mevalonate pathway, Nature,
343, 425-430.
[51] Chester BG (2002) Polypharmacy in Elderly Patients with Diabetes, Diabetes Spec‐
trum, 15, 240-248.
[52] Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA and
Blasetto JW (2003) Comparison of the efficacy and safety of rosuvastatin versus ator‐
vastatin, simvastatin, and pravastatin across doses, Am. J. Cardiol., 92, 152-160.
[53] Caslake MJ, Stewart G, Day SP, Daly E, McTaggart F, Chapman MJ, Durrington P,
Laggner P, Mackness M, Pears J and Packard CJ (2003) Phenotype-dependent and in‐
dependent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperli‐
pidaemia, Atherosclerosis,171, 245-253.
[54] 54 Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L and Lindgarde F (2002) Ef‐
fects of cholesterol and inflammation-sensitive plasma proteins on incidence of myo‐
cardial infarction and stroke in men, Circulation, 105, 2632-2637.
[55] Dangas G, Smith DA, Unger AH, Shao JH, Meraj P, Fier C, Cohen AM, Fallon JT,
Badimon JJ and Ambrose JA (2000) Pravastatin: an antithrombotic effect independent
of the cholesterol lowering effect, Thromb Haemost., 83, 688-692.
[56] Honjo M, Tanihara H, Nishijima K, Kiryu J, Honda Y, Yue BY and Sawamura T
(2002) Statin inhibits leukocyte-endothelial interaction and prevents neuronal death
induced by ischemia-reperfusion injury in the rat retina, Arch. Ophthalmol., 120,
1707-1713.
Hypercholesterolemia220
[57] 67 Delanty N, Vaughan CJ and Sheehy N (2001) Statins and neuroprotection, Expert
Opin. Investig. Drugs, 10, 1847-1853.
[58] Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection
Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a
randomised placebo-controlled trial, Lancet, 360, 7-22.
[59] Chong PH (2002) Lack of Therapeutic Interchangeability of HMG-CoA Reductase In‐
hibitors, Ann. Pharmacother., 36, 1907-1917.
[60] Poulter N (1999) Coronary heart disease is a multifactorial disease. Am. J. Hyper‐
tens., 12, 92S-95S.
[61] Lloyd-Jones DM, Evans JC and Larson MG (1999) Cross-classification of JNC VI
blood pressure stages and risk groups in the Framingham Heart Study, Arch. Intern.
Med., 159, 2206-2212.
[62] Wilson PW, Kannel WB, Silbershatz H and D’Agostino RB (1999) Clustering of meta‐
bolic factors and coronary heart disease, Arch. Intern. Med., 159, 1104-1109.
[63] Thomas F, Bean K and Guize L (2002) Combined effects of systolic blood pressure
and serum cholesterol on cardiovascular mortality in young (<55 years) men and
women, Eur. Heart J., 23, 528-535.
[64] Wood D, Durrington P and McInnes G (1998) Joint British recommendations on pre‐
vention of coronary heart disease in clinical practice, Heart, 80(Suppl. 2), S1-S29.
[65] Kannel WB (2000) Risk stratification in hypertension: New insights from the Fra‐
mingham Study. Am. J. Hypertens., 13, 3S-10S.
[66] Grundy SM, Brewer HB, Cleeman JI, Smith SC and Lenfant C (2004) Definition of
metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/Ameri‐
can Heart Association conference on scientific issues related to definition, Circula‐
tion, 109,433-438.
[67] Lars-Christian R, Elena B, Boguslaw O, Marianne W, Albert K and Philippe F (2008)
Coadministration of Valsartan 160 and 320 mg and Simvastatin 20 and 40 mg in Pa‐
tients with Hypertension and Hypercholesterolemia: A Multicenter, 12-Week, Dou‐
ble-Blind, Double-Dummy Parallel Group Study, Clinical Therapeutics, 30, 10.
[68] Cefalu WT (2008) Diabetic dyslipidemia and the metabolic syndrome, Diab. Metab.
Synd. Clin. Res. Rev., 2, 208-222.
[69] Marcus AO (2000) Safety of drugs commonly used to treat hypertension, dyslipide‐
mia, and type 2 diabetes (The Metabolic Syndrome): Part 1, Diabetes Technol. Ther.,
2, 101-110.
[70] Grundy SM, Cleeman JI, Daniels SR, Donato KA, R Eckel H, Franklin BA, Gordon DJ,
Krauss RM, Savage PJ, Smith SC, Spertus JA and Costa F (2005) Diagnosis and Man‐
agement of the Metabolic Syndrome, Circulation, 112, 2735-2752.
Interaction Studies of ACE Inhibitors with Statins
http://dx.doi.org/10.5772/59491
221
[71] Plosker GL and Robinson DM (2008) Amlodipine/valsartan, fixed-dose combination
in hypertension, Drugs, 68, 373.
[72] Jacobson TA (2004) Comparative pharmacokinetic interaction profiles of pravastatin,
simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors,
Am. J. Cardiol., 94(9), 1140-6.
[73] Markham A and Goa KL (1997) Valsartan: A review of its pharmacology and thera‐
peutic use in essential hypertension, Drugs, 54, 299-311.
[74] Pool JL, Glazer R, Chiang YT and Gatlin M (1999) Dose-response efficacy of valsar‐
tan, a new angiotensin II receptor blocker, J. Hum. Hypertens., 13, 275-281.
[75] Burnier M and Brunner HR (2000) Angiotensin II receptor antagonists, Lancet, 355,
637-645.
[76] Weir MR, Crikelair N and Levy D (2007) Evaluation of the dose response with valsar‐
tan and valsartan/hydrocholorothia- zide in patients with essential hypertension. J.
Clin. Hypertens., 9, 103-112.
[77] Dorval JF, Anderson T and Buithieu J (2005) Reaching recommended lipid and blood
pressure targets with amlodipine/atorvastatin combination in patients with coronary
heart disease, Am. J. Cardiol., 95, S249-S253.
[78] Koh KK, Quon MJ and Han SH (2004) Additive beneficial effects of losartan com‐
bined with simvastatin in the treatment of hypercholesterol-emic, hypertensive pa‐
tients, Circulation, 110, 3687-3692.
[79] Borghi C, Dormi A and Veronesi M (2002) Use of lipid-lowering drugs and blood
pressure control in patients with arterial hypertension, J. Clin. Hypertens., 4, 277-285.
[80] Gotto Jr. AM (1998) Risk factor modification: rationale for management of dyslipide‐
mia, American Journal of Medicine, 104, 6S-8S.
[81] Gould KL, Casscells SW, Buja LM and Goff DC (1995) Non-invasive management of
coronary artery disease: Report of a meeting at the University of Texas Medical
School at Houston, Lancet, 346, 750-753.
[82] Wood D (2001) Asymptomatic individuals’ risk stratification in the prevention of cor‐
onary heart disease, British Medical Bulletin, 59, 3-16.
[83] Pan HY, Triscari J and DeVault AR (1991) Pharmacokinetic interaction between pro‐
pranolol and HMG-CoA reductase inhibitor pravstatin and lovastatin, Br. J. Clin.
Pharmacol., 31, 665-670.
[84] O’Riordan M (2005) ASCOT-LLA: Lower coronary event rates in patients treated
with amlodipine and atorvastatin, Hypertension, Medscape, Medical News.
[85] Sultana N, Arayne MS and Safila Naveed (2010) Simultaneous Determination of Cap‐
topril and Statins in API, Pharmaceutical Formulations and in Human Serum by RP-
Hypercholesterolemia222
HPLC, J. Chin. Chem. Soc., 57, 378-383. [online] Available at: http://
onlinelibrary.wiley.com/doi/10.1002/jccs.201000056/abstract
[86] Sultana N, Arayne MS and Safila N. (2011) Simultaneous Determination of Enalapril
and Statins in Pharmaceutical Formulations by RP- HPLC, Chilean Chemical Society,
56(3), 734-737. [online] Available at:. http://www.scielo.cl/scielo.php?script=sci_art‐
text&pid=S0717-97072011000300003
[87] Sultana N, Arayne MS, Shah SN and Safila N. (2010) Simultaneous Determination of
Prazosin, Atorvastatin, Rosuvastatin and Simvastatin in API, Dosage Formulations
and Human Serum by RP-HPLC, Journal of the Chinese Chemical Society, 57(6),
1286-1292. [online] Available at: http://onlinelibrary.wiley.com/doi/10.1002/jccs.
201000190/abstract
[88] Sultana N, Arayne MS and Safila N. (2011) Validated Method for the Simultaneous
Determination of Lisinopril, Pravastatin, Atorvastatin and Rosuvastatin in API, For‐
mulations and Human Serum by RP-HPLC, Chinese Journal of Chemistry, 29,
1216-1220. DOI: 10.1002/cjoc.201190226. [online] Available at: http://onlineli‐
brary.wiley.com/doi/10.1002/cjoc.201190226/abstract
Interaction Studies of ACE Inhibitors with Statins
http://dx.doi.org/10.5772/59491
223

